Characteristics and outcomes of SARS-COV 2 critically ill patients after emergence of the variant of concern 20H/501Y.V2
A comparative cohort study

Philippe Aries, MD\textsuperscript{a,b,c,*}, Olivier Huet, MD, PhD\textsuperscript{b,c}, Julien Balicchi, Quentin Mathais, MD\textsuperscript{d}, Camille Estagnasie\textsuperscript{e}, Gonzague Martin-Lecamp\textsuperscript{a}, Olivier Simon, MD\textsuperscript{f}, Anne-Cécile Morvan, MD\textsuperscript{g}, Bérénice Puech, MD\textsuperscript{h}, Marion Subiros\textsuperscript{j}, Renaud Blonde, MD\textsuperscript{k}, Yvonnick Boue, MD\textsuperscript{m}

Abstract
There are currently no data regarding characteristics of critically ill patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant of concern (VOC) 20H/501Y.V2. We therefore aimed to describe changes of characteristics in critically ill patients with Covid-19 between the first and the second wave when viral genome sequencing indicated that VOC was largely dominant in Mayotte Island (Indian Ocean). Consecutive patients with Covid-19 and over 18 years admitted in the unique intensive care unit (ICU) of Mayotte during wave 2 were compared with an historical cohort of patients admitted during wave 1. We performed a LR comparing wave 1 and wave 2 as outcomes. To complete analysis, we built a Random Forest model (RF), that is, a machine learning classification tool- using the same variable set as that of the LR. We included 156 patients, 41 (26.3%) and 115 (73.7%) belonging to the first and second waves respectively. Univariate analysis did not find difference in demographic data or in mortality. Our multivariate LR found that patients in wave 2 had less fever (absence of fever aOR 5.23, 95\% confidence interval (CI) 1.89–14.48, \( p = .001 \)) and a lower simplified acute physiology score (SAPS II) (aOR 0.95, 95\% CI 0.91–0.99, \( p = .007 \)) at admission; at 24 hours, the need of invasive mechanical ventilation was higher (aOR 3.49, 95\% CI 0.98–12.51, \( p = .055 \)) and pO2/FIO2 ratio was lower (aOR 0.99, 95\% CI 0.98–0.99, \( p = .03 \)). Patients in wave 2 had also an increased risk of ventilator-associated pneumonia (VAP) (aOR 4.64, 95\% CI 1.54–13.93, \( p = .006 \)). Occurrence of VAP was also a key variable to classify patients between wave 1 and wave 2 in the variable importance plot of the RF model. Our data suggested that VOC 20H/501Y.V2 could be associated with a higher severity of respiratory failure at admission and a higher risk for developing VAP. We hypothesized that the expected gain in survival brought by recent improvements in critical care management could have been mitigated by increased transmissibility of the new lineage leading to admission of more severe patients. The immunological role of VOC 20H/501Y.V2 in the propensity for VAP requires further investigations.

Abbreviations: AUROC = area under the receiver operating characteristic curve, CI = confidence interval, ICU = intensive care unit, LR = logistic regression, MDA = mean decrease accuracy, MDG = mean decrease gini, NIV = non-invasive ventilation, SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2, SAPS II = simplified acute physiology score, SOFA = sequential organ failure assessment, VAP = ventilator-associated pneumonia, VOC = variant of concern.

Keywords: COVID-19; variant; critically-ill patients
1. Introduction
The coronavirus disease 2019 (Covid-19) pandemic continues in the world, with recent estimates of more than 268 million cases diagnosed and more than 5 million deaths.[11] Multiple variants of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Covid-19, have been observed worldwide. A variant has one or more mutations that differentiate it from the ancestral ribonucleic acid virus and from other variants. Among them, variant 20H/S01Y.V2 (also known as variant Beta or B.1.351) has been characterized as a variant of concern (VOC) that is a variant for which there is evidence of an increase in transmissibility, an increase in symptom severity (e.g., increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.[2]

Variant 20H/S01Y.V2 is associated with multiple mutations in spike protein[3] and emerged in September 2020 in South Africa[4] before spreading worldwide. Variant 20H/S01Y.V2 was the most common strain in some French regions between April and May 2021.[5]

There are currently limited data regarding clinical differences between Covid-19 disease caused by different variants especially for VOC 20H/S01Y.V2. This VOC has been associated with an increased severity of the disease and increased in-hospital mortality[6,7] especially in patients older than 60 years.[8] However, clinical characteristics of critically ill patients remain undescribed.

Mayotte Island is an overseas department of France located in the Indian Ocean. The first case of Covid-19 was diagnosed in week 11, 2020 and the epidemic peak of the first wave was reached in May 2020. A few weeks after the emergence of the VOC 20H/S01Y.V2 in South Africa, Mayotte Island experienced a new and more dramatic second wave, which peaked in week 5, 2021. During week 5 and week 6, all SARS-Cov-2 positive samples were analyzed and more than 80% of them (150/172) pointed to 20H/S01Y.V2 variant. Moreover, in the same period viral whole genome sequencing was performed for 23 critically ill patients: 87% (N = 20) were infected by the 20H/S01Y.V2 variant.[9,10] Therefore VOC 20H/S01Y.V2 was considered dominant during the second wave in Mayotte Island. The intensive care unit (ICU) of the Mayotte's Hospital, a 16 beds unit, is the unique structure for critically ill patients on the island. This specificity allowed us to make a rigorous comparison between both waves and avoided interhospital variability previously reported in epidemiological studies for Covid-19 patients.[11,12]

We therefore aimed to describe changes in the characteristics of critically ill patients with Covid-19 after the emergence of the VOC 20H/S01Y.V2 by comparing the clinical profile of patients hospitalized during the first and second waves of the SARS-Cov-2 pandemic.

2. Methods
2.1. Study design, waves, and subjects definitions
We performed a comparative cohort study in the Mayotte Hospital. All consecutive patients over 18 years of age admitted in ICU with laboratory-confirmed (SARS-CoV-2) infection were retrospectively included in wave 1 and prospectively included in wave 2. The waves periods were defined using ICU admission data. The first wave was the period from the start of the pandemic, that is, March 15, 2020 (W12-2020) to September 27, 2020 (W39-2020); and the second wave was defined from February 01, 2021 (W5-2021 to March 01, 2021 (W9-2021).

Wave 2 was considered starting when viral whole genome sequencing results indicated that VOC 20H/S01Y.V2 was predominant in Mayotte Island[8,10] as it has been in South Africa.[3] Patients admitted to ICU between these two periods were excluded to avoid risk of overlap between infection by Beta variant and the wild type virus. Laboratory confirmation for SARS-CoV-2 was defined as a positive result of real-time reverse transcriptase-polymerase chain reaction assay from either nasal or pharyngeal swabs, or lower respiratory tract samples.

Our study received approval from the ethical committee of the French Society of Anesthesia and Intensive Care Medicine (IRB 00010254 - 2021–080) in accordance with our local regulations. All patients or close relatives were informed that their data were included in the study when possible.

Reporting of the study followed the strengthening of the reporting of observational studies in epidemiology guidelines.[12]

2.2. Data collection and outcomes
We collected in health care records demographic data, medical history, comorbidities, the clinical frailty scale (a patient with a score ≥5 was considered frail[13]) and symptoms before admission. We also collected signs at admission, ROX index for patients under oxygen therapy,[14] laboratory results and computed tomography scans (visual quantification was used to classify patients as per the percentage of lung parenchyma affected[15,16] at admission.

Disease severity at ICU admission was evaluated using sequential organ failure assessment (SOFA) score, WHO Clinical Progression Scale,[17] and simplified acute physiology score (SAPS II) score. SOFA score and WHO Clinical Progression Scale were also evaluated at 24 hours of ICU admission.

Clinical evolution at 24-hours, use of adjunct measures (i.e., corticosteroids, neuromuscular blockers, nitric oxide, invasive therapies, prone positioning) and in-hospital complications (i.e., myocarditis, bradycardia under 50 bpm, neurocovid defined as SARS-Cov-2 positive samples in cerebrospinal fluid, thrombosis, coinfections and bacterial cultures results) were also recorded. A diagnosis of ventilator-associated pneumonia (VAP) was made in case of clinical and radiological signs associated to bacterial documentation. Finally, we evaluated the following outcomes: duration of mechanical ventilation, Ventilator-free days at 28 days (VFD28) (defined as the number of days with successful cessation (alive and free) from invasive mechanical ventilation for at least 48 hour without reintubation in patients who survived 28 days after ICU admission, whereas for patients ventilated 28 days or more, or who died within 28 days ventilator-free days were zero), the need for medical evacuation, the dates of ICU and hospital discharge, and vital status at 28 days after ICU admission.

In case of Aero-medical evacuation for patient, the three receiving hospitals (University Teaching Hospital of Saint Pierre, La Réunion, University Teaching Hospital of Saint Denis, La Réunion and Hospital of Western Réunion) collected data using the same definitions.

2.3. Statistical analysis
No statistical sample size calculation was made and sample size was equal to the number of patients admitted to the ICU during both defined periods. Characteristics of patients were described as frequencies and percentages for categorical variables, as means and standard deviations or medians and interquartile ranges for continuous variables. Categorical variables were compared by Chi-square or Fisher’s exact test. After testing for normality (Kolmogorov–Smirnov test) and for equality of variances (Fisher–Snedecor test), continuous variables were compared either by Student’s t test, Welch’s t-test or Wilcoxon’s rank-sum test. Tests were two-sided and values of p < .05 were considered statistically significant. Missing data was not imputed.

In order to compare the characteristics of Covid-19 patients admitted to ICU during wave 1 and wave 2, we...
performed a logistic regression (LR). Variables significantly associated in bivariate analysis with a value of \( p < .10 \) and with less than 10% missing data were included in the LR model. Results were presented as adjusted odds ratios (aOR) with their 95% confidence intervals (OR, 95% confidence interval [CI]).

To complete analysis of changes in characteristics and outcomes, we built a Random Forest model (RF) that is, a machine learning classification tool using the same variable set as that of the LR.

Random Forest built a multitude of decision trees based on bootstrap sampling of the training dataset. The variables in each tree were randomly selected. Algorithm aggregated the results of multiple decision trees via majority voting.\(^\text{[19]}\) We set the number of multiple decision trees as 5000 and the number of variables used in a decision tree was 2. The RF model can provide importance ranking of the predictor variables using the mean decrease accuracy (MDA) plot and the mean decrease in gini (MDG) coefficient. The MDA plot expresses for all variable how much accuracy the model losses by excluding the variable. The more the accuracy suffers, the more important the variable is for classification. The MDG coefficient is a measure of how a variable contributes to the homogeneity of the nodes and leaves in the Random Forest model. The higher the value of MDA of MDG for a variable, the higher the importance of the variable in the model.

The prediction performance of the models was assessed by the area under the receiver operating characteristic curve (AUROC).

The statistical analysis was implemented using SAS (Enterprise Guide 7.11) and R (1.1.463).

3. Results
We included 156 patients among 190 assessed for eligibility, 41 during the first wave and 115 during the second wave. Thirty-four patients were excluded for risk of overlap between variant and wild-type virus. Six patients enrolled were lost to follow-up at Day-28 (Fig. 1).

During the first wave, the peak of weekly new admissions in ICU reached in W21-2020 with 8 new patients admitted in a week. During the second wave in 2021, hospital was rapidly overloaded and the peak in ICU was reached in W7-2021 with 36 new patients admitted (Fig. 2).

3.1. Univariate analysis of characteristics and outcomes
We did not observe significant differences in basic demographic data and comorbidities between both waves (Table 1). However, during the second waves, patients had less fever before admission and at ICU admission (47 vs 73.2% before admission, \( p = .007 \) and 31.9 vs 58.5% at admission, \( p = .005 \)). The rate of patients with invasive mechanical ventilation and pO2/FiO2 ratio <150 mmHg at admission (WHO Clinical Progression Scale) was higher during wave 2 (14.6 vs 21.7% \( p = .03 \)). We did not find difference concerning laboratory results and comparison of percentage of lung parenchyma affected was not possible because of the proportion of missing data during the first wave (44.7%).

Analysis of adjunct measures showed differences between both waves with much more days of continuous neuromuscular blockade (7.51 vs 6.89 days, \( p = .029 \)), more use of corticosteroids (100 vs 20%, \( p < .001 \)), and nitric oxide use.
(20 vs 2.4%, \(p = .015\)) during wave 2. The second wave was also associated with an increased rate of VAP (57.4 vs 26.8%, \(p = .001\)).

We did not find significant difference for outcomes except for the rate of Aero-medical evacuation that was significantly higher during wave 2 (58.3 vs 7.7%, \(p < .001\)) (Table 2).

3.2. Multivariate analysis of characteristics and outcomes according to the wave

Our logistic regression analysis found that patients in wave 2 had less fever (aOR absence of fever: 5.23, 95% CI 1.89–14.48, \(p = .0014\)), a lower SAPS II at admission (aOR 0.95, 95% CI 0.91–0.99, \(p = .0075\)). Concerning outcomes, we found that wave 2 was associated with a higher rate of invasive mechanical ventilation at 24 hours (aOR 3.49, 95% CI 0.98–12.51, \(p = .055\)), a lower pO2/FiO2 ratio at 24 hours (aOR 0.99, 95% CI 0.98–0.99, \(p = .0309\)) and an increased risk of VAP (aOR 4.64, 95% CI 1.54–13.93, \(p = .0063\)) (Table 3). The AUROC for LR model was 0.797, and accuracy was 82% (Table 4).

3.3. Contribution of machine learning model in determination of waves characteristics

Variable importance plot based on Random Forest model showed that absence of fever at admission and VAP were the most important variables to classify patients between wave 1 and wave 2 (Fig. 3). The AUROC for RF model was 0.678 (Table 4).

4. Discussion

To our knowledge, this is the first study to report changes in the characteristics of critically ill patients with acute respiratory failure due to Covid-19 after the emergence of the VOC 20H/501Y.V2. Demographic characteristics were similar between both waves, and our multivariate analysis associated with a machine learning method found that patients of wave 2 had less fever and had a lower illness severity score SAPS II at admission, but they were also more hypoxemic and more mechanically ventilated at 24 hours after admission and finally developed more VAP during their ICU stay.

Experience gained during the first wave and specific therapies have been associated to a better outcome among critically ill Covid-19 patients admitted during second waves across the world.[20–22] Among these therapies, the introduction of corticosteroids have been associated to a lower proportion of patients requiring invasive mechanical ventilation and to reduced mortality.[23] Interestingly, despite implementation of a protocol for corticosteroids in our ICU, we did not found difference of mortality between both waves.

It has been suggested that VOC 20H/501Y.V2 could be associated to a higher hospital morbidity and mortality rate,[26,27] therefore in our study the expected gain in survival brought by improvements in critical care management could have been mitigated by increased severity of the new lineage. However, changes in morbidity and mortality rates of patients with SARS-CoV-2 infection should be interpreted with caution. Independently of virus virulence, Covid-19 outcomes can largely be affected by the epidemiological context, that is, population structure, climate, and social practice for example.[28] The observational nature of previous studies implies possible unmeasured confounders factors. Moreover, hospital mortality and ICU mortality can differ largely because of very different fatality rates. In our study, higher rate of VAP, increased duration of invasive mechanical ventilation and of ICU length of stay could have directly contributed to mitigate outcome improvement.

We observed that despite similar SOFA score and slightly decreased SAPS II at admission, patients in wave 2 needed more invasive mechanical ventilation (aOR 3.49, 95% CI 0.98–12.51, \(p = .055\)) and had a lower pO2/FiO2 ratio at 24 hours (aOR 0.99, 95% CI 0.98–0.99, \(p = .0309\)). These results are in line with a recent study of Carbonell et al, comparing mortality in ICU between waves in a multicenter retrospective cohort. Authors found a significant lower illness severity at
admission but also a trend for an increased severity of respiratory failure at admission (lower pO2/FiO2 ratio) during wave 2 and 3 in Europe when higher incidence of cases led to ICU overload.\[29\]

During wave 2, when VOC 20H/501Y.V2 was the dominant lineage, Mayotte Island experienced a rapid and intense deterioration of the epidemiological situation. At the epidemic peak, reached in the first weeks of February, incidence rate was 8.5/100,000, (i.e., 2378 new confirmed cases in the week) and positive rate was 28%.\[9\] The unique hospital of Mayotte was rapidly overloaded with a peak of new admissions reached in W6-2021 (225 patients hospitalized including 30 to ICU). For comparison during the peak of wave 1, 54 patients were hospitalized including 8 in ICU in a week.\[10\] This epidemiological situation could be explained by an increased transmissibility of VOC 20H/501Y.V2 compared to wild lineage.\[4\]

We observed that delay between first signs and hospital admission was increased during wave 2, 7 days (4–9) versus 6 days (3–8). As previously suggested, in an overwhelmed health system, individuals might avoid seeking care until later stage of disease.\[27\]

### Table 1

Demographic, clinical, and ventilatory support characteristics at admission of patients according to the wave.

|                      | First wave (n = 41) | Second wave (n = 115) | P value |
|----------------------|---------------------|-----------------------|---------|
| Patient’s characteristics |                     |                       |         |
| Sex—no. (%)          |                     |                       |         |
| Male                 | 26 (63.4)           | 73 (63.5)             | 1.00    |
| Female               | 15 (36.6)           | 42 (36.5)             |         |
| Age, yr              | 60 (51–67)          | 57 (46–66)            | .66     |
| Body mass index, kg/m² | 28 (24–33.09)      | 29.40 (26.53–34.70)  | .22     |
| Known diabetes       | 22 (53.7)           | 59 (61.3)             | .94     |
| Trained hypertension | 25 (61.0)           | 63 (54.8)             | .62     |
| Immunodeficiencya    | 2 (4.9)             | 6 (5.2)               | 1.00    |
| Chronic kidney disease | 8 (19.5)          | 11 (9.6)              | .16     |
| Dialysis             | 1 (2.4)             | 1 (0.9)               | 1.00    |
| Chronic respiratory disease | 1 (2.4)    | 7 (6.1)               | .61     |
| Active smokers       | 1 (2.4)             | 5 (4.3)               | .94     |
| Pregnancy            | 1 (2.4)             | 6 (5.2)               | .77     |
| Clinica frailt scale >5 | 0 (0)             | 7 (6.06)              | .43     |
| Symptoms before ICU admission |     |                       |         |
| Cough                | 22 (53.7)           | 74 (64.3)             | .31     |
| Shortness of breath  | 37 (90.2)           | 112 (97.4)            | .15     |
| Chest pain           | 3 (7.3)             | 7 (6.1)               | 1.00    |
| Anemia, ageusia      | 3 (7.3)             | 11 (9.6)              | .90     |
| Myalgia              | 6 (14.6)            | 12 (10.4)             | .66     |
| Fever                | 30 (73.2)           | 54 (47.0)             | .007    |
| Headaches            | 9 (22.0)            | 23 (20.0)             | .97     |
| Diarrhea             | 2 (4.9)             | 7 (6.1)               | 1.00    |
| Altered mental function | 3 (7.3)           | 11 (9.6)              | .91     |
| Vomiting             | 2 (5.0)             | 6 (5.2)               | 1.00    |
| Clinical characteristics and ICU Scores at admission |     |                       |         |
| Delay between first symptoms and ICU admission | 6 (3–8)             | 7 (4–9)               | .25     |
| Fever                | 24 (58.5)           | 36 (31.9)             | .005    |
| IGS2 score           | 39 (32–49)          | 35 (29–41)            | .08     |
| SOFA score           | 3 (2–5)             | 3 (2–4)               | .62     |
| WHO clinical progression scale | 4 (9.8)           | 1 (0.9)               | .03     |
| Oxygen by mask or nasal prongs | 29 (70.7)          | 79 (68.7)             |         |
| Oxygen by NIV or High flow | 2 (4.9)             | 10 (8.7)              |         |
| Mechanical ventilation, pO2/FiO2 mm Hg > 150 | 6 (14.6)           | 25 (21.7)             |         |
| Mechanical ventilation, pO2/FiO2 mm Hg < 150 | 4.3 (2.9–6.9)     | 4.19 (3.4–4.8)        | .13     |
| Laboratory parameters at admission |     |                       |         |
| pO2/FiO2 mm Hg       | 129 (84–180)        | 99.5 (78–128)         | .08     |
| Fibrinogen           | 6.89 (5.62–8.3)     | 6.65 (5.84–7.59)      | .40     |
| Lymphocyte count >4,8 × 10⁹/L | 26 (66.7)          | 88 (80)               | .09     |
| CPK                  | 158 (75–237)        | 272 (114–890)         | .12     |
| Troponin             | 0.03 (0.01–0.08)    | 0.02 (0.01–0.06)      | .40     |
| CT lung lesions at admission |     |                       |         |
| Percentage of lung parenchyma affected |     |                       |         |
| <25%                 | 0 (0.0)             | 13 (11.7)             |         |
| 25–50%               | 8 (21.1)            | 28 (25.2)             |         |
| 50–75%               | 10 (26.3)           | 45 (40.5)             |         |
| >75%                 | 3 (7.9)             | 15 (13.5)             |         |
| Non available data   | 17 (44.7)           | 4 (3.6)               |         |
| No CT scan           | 0 (0.0)             | 6 (5.4)               |         |

Results are expressed as n (%) or median (25th–75th percentiles).

CPK = Creatine Phosphokinase, CT = computed tomography, ICU = intensive care unit, NIV = non-invasive ventilation, SAPS = simplified acute physiology score, SOFA = sequential organ failure assessment.

a Defined as hematological malignancies, active solid tumor, or having received specific anti-tumor treatment within a year, solid-organ transplant, human immunodeficiency virus, or immunosuppressants.
Therefore, we hypothesize that increased transmissibility of VOC 20H/501Y.V2 during wave 2 led to hospital and ICU capacity overload and thus to admission of patients with more severe respiratory failure.

An important finding of the study was that, using the same definition of VAP between both cohorts, we found a much higher incidence of VAP during the second wave compared to the first wave (57.4% vs 26.8%, \( p = .001 \)). VAP was independently associated with wave 2 (aOR 4.64, 95 CI 1.54–13.93, \( p = .0063 \)) after adjusting for invasive ventilation and pO2/FiO2 ratio at 24 hours. In a recent multicentric cohort comparing mortality between three waves in critically ill patients, Carbonell et al. also found an increased rate of VAP during second and third waves in Europe.\(^{[29]}\) The large use of immunosuppressive agents (corticosteroids) during wave 2 could explain this finding. However, Ritter et al., showed in an observational study, after adjusting for competing risks, that corticosteroids seemed to have no impact on the likelihood of developing VAP.\(^{[32]}\)

### Table 2

**Evolution at 24 hours, Use of adjunct measures, Major complications and outcomes during ICU stay.**

|                      | First wave (n = 41) | Second wave (n = 115) | \( P \) value |
|----------------------|---------------------|-----------------------|--------------|
| **Clinical characteristics and Score at 24 hr** |                      |                       |              |
| SOFA score           | 4 (2–6)             | 4 (2–6)               | .90          |
| ROX index (for patients under oxygen therapy) | 6.85 (4.79–8.8)     | 6.05 (5.05–9.57)      | .64          |
| Invasive mechanical ventilation | 27 (65.9)          | 97 (84.3)             | .01          |
| WHO clinical progression scale |                       |                       | .57          |
| Oxygen by mask or nasal prongs | 1 (2.4)            | 3 (2.6)               |              |
| Oxygen by NIV or High flow | 18 (43.9)          | 33 (28.7)             |              |
| Mechanical ventilation, \( po2/Fio2/\text{mm Hg} > 150 \) | 11 (26.8)          | 35 (30.4)             |              |
| Mechanical ventilation, \( po2/Fio2/\text{mm Hg} < 150 \) | 10 (24.4)          | 39 (33.9)             |              |
| **Blood gases at 24 hr** |                      |                       |              |
| pH                   | 7.43 (7.36–7.47)    | 7.42 (7.37–7.47)      | .70          |
| PaCO2, \text{mm Hg}  | 38 (32–43)          | 40.5 (35–45)          | .15          |
| HCO3, mmol/\text{L}  | 26 (22–28)          | 27.10 (24–29.9)       | .02          |
| Lactate, mmol/\text{L} | 1.2 (0.9–1.5)    | 1.4 (1.1–1.7)         | .02          |
| PaO2/FiO2             | 150 (121–215)       | 136 (105–175)         | .06          |
| **Adjunct measures**  |                      |                       | <.001        |
| Corticosteroids       | 8 (20.0)            | 112 (100.0)           |              |
| Continuous neuromuscular blockade, days | 3 (1–6)         | 6 (1–12)              | .01          |
| Prone positioning, days | 1 (0–2)           | 2 (0–4)               | .12          |
| ECMO                 | 2 (0.0)             | 4 (0.03)              | .40          |
| Tracheotomy          | 7 (17.1)            | 13 (11.3)             | .50          |
| Nitric oxide         | 1 (2.4)             | 23 (20.0)             | .02          |
| **Major complications during ICU stay** |                      |                       |              |
| Myocarditis          | 1 (2.7)             | 8 (7.0)               | .58          |
| Days between myocarditis onset and first symptoms | 14.00 (8.5–19.5) | 9.5 (7.5–14) | .20 |
| Bradycardia\(^{a}\) | 1 (2.7)             | 17 (14.8)             | .09          |
| Neurocovid\(^{b}\)  | 0 (0.0)             | 1 (3.4)               | 1.00         |
| Thrombosis\(^{d}\)   |                      |                       | .06          |
| Venous               | 0 (0.0)             | 9 (8.2)               |              |
| Pulmonary embolism   | 0 (0.0)             | 3 (2.7)               |              |
| Artery               | 1 (4.3)             | 0 (0.0)               |              |
| Ventilator Associated Pneumonia | 11 (26.8) | 66 (57.4)             | .001         |
| **Outcomes**         |                      |                       |              |
| Duration of invasive ventilation, days | 13 (7–24)          | 17 (10–28)            | .28          |
| VFD28                | 0.5 (0–8)           | 0 (0–13)              | .97          |
| ICU length of stay, days | 9 (6–27)         | 16 (9.5–28)           | .09          |
| Hospital length of stay, days | 20 (10–31)     | 19 (12–31)            | .65          |
| Day 28 mortality     | 10 (25.6)           | 36 (31.3)             | .64          |
| Arno-medical evacuation | 3 (7.7)          | 67 (58.3)             | <.001        |

Results are expressed as n (%) or median (25th–75th percentiles).

ECMO = extracorporeal membrane oxygenation, ICU = intensive care unit, NIV = non-invasive ventilation, SOFA = sequential organ failure assessment, VFD28 = ventilator-free days at 28 days.

\(^{a}\)According to RECOVERY protocol\(^{[38]}\).

\(^{b}\)Bradycardia under 50 bpm.

\(^{c}\)SARS-Cov-2 positive samples in cerebrospinal fluid.

\(^{d}\)Proven venous or arterial thrombosis.

### Table 3

**Multivariate analysis of factors associated with wave 2**

| Clinical features                          | OR [95% CI]        | \( p \) value |
|-------------------------------------------|-------------------|---------------|
| Absence of fever at admission             | 5.23 [1.89; 14.48] | .0014         |
| SAPS I at admission                       | 0.95 [0.91; 0.99]  | .005          |
| Invasive mechanical ventilation at 24 hours | 3.49 [0.98; 12.52] | 0.050         |
| pO2/FiO2 ratio at 24 hours                | 0.99 [0.96; 0.99]  | 0.030         |
| VAP                                       | 4.64 [1.54; 13.93] | .0063         |

CI = confidence interval, SAPS = simplified acute physiology score, VAP = ventilator acquired pneumonia.
The higher rate of VAP during wave 2 could also be explained by an increased rate of invasive mechanical ventilation during the first 24 hours and with an increased duration of mechanical ventilation.

Finally, it is possible that VOC 20H/501Y.V2 itself played a role immunologically in the propensity for VAP. Indeed, it has been reported that critically-ill patients with Covid-19 patients suffered from a considerable burden of immunoparesis, due to impaired immune cell function.\cite{33,34} Since the beginning of the surge, the incidence of VAP is found higher in patients with SARS-CoV-2 infection, as compared to patients with influenza pneumonia, or no viral infection.\cite{35,36} However, to date, specific

### Table 4

| Model          | Variables                                                                 | AUROC  | Specificity | Sensibility | NPV  | PPV  | Model accuracy | N                  | Parameters                  |
|---------------|---------------------------------------------------------------------------|--------|-------------|-------------|------|------|----------------|------------------------|--------------------------------|
| Logistic regression | Fever at admission + SAPS* II + IMV* + paO2/FiO2 ratio* + VAP             | 0.797  | 36%         | 96%         | 75%  | 83%  | 82%            | n = 131                | (wave 1 = 32; Wave 2 = 99) |
| Random forest  | Fever at admission + SAPS* II + IMV* + paO2/FiO2 ratio* + VAP              | 0.678  | 28%         | 95%         | 64%  | 80%  | 77%            | n = 131                | (wave 1 = 32; Wave 2 = 99)  |

AUROC = area under receiver operating curve, IMV = invasive mechanical ventilation, OOB = out of bag, PLS = partial least squares, VAP = ventilator-associated pneumonia.

*At 24 hours.
effect on immune response of variants in critically-ill patients remains non-investigated.

The rate of comorbidities in our population was in line with previous studies except for diabetes, more frequent than previously reported.\cite{38,37} Mayotte is the poorest and most densely populated territory in France with poor socio-economic and health conditions and prevalence of comorbidities such as diabetes is high.\cite{38} Interestingly, although second waves across the world have been frequently associated to younger patients with fewer comorbidities\cite{38} we did not observe difference in demographic data between both waves. It has been proposed that the most vulnerable patients as older people and those with comorbidities were likely to die during first waves.\cite{39} However, wave 1 in Mayotte was much less intense than in other regions of the world. Therefore, specificities of the epidemic in Mayotte could explain the absence of change in profile of Covid-19 critically-ill patients between both waves.

Our study has some important strengths. First, to our knowledge, we describe for the first-time clinical characteristics and outcomes of critically ill patients with VOC 20H/501Y.V2. Second, we performed a detailed report of physiological, clinical features, and ventilatory management using the recent recommended WHO Clinical Progression Scale that has been developed to facilitate data pooling across cohort studies and clinical trials.\cite{17,13} Third, we found similar typology of the patients at admission during both waves making relevant the comparison of outcomes. Fourth, the proportion of missing data was very low. Fifth, we performed the comparison between both waves in the only ICU of the island avoiding hospital variability previously described for Covid-19 patients.\cite{11}

Lastly, addition of a machine learning method to the logistic regression allowed to improve characterization of variables associated to wave 2. Contrary to other machine learning classification tools, the logic of RF algorithm is understandable for clinicians, moreover RF model can provide importance ranking of the variables.

We acknowledge several limitations to our study. First, we performed a retrospective analysis with risk of mis-classification bias. Second, our study took place in Mayotte Island, potentially limiting generalizability to other hospitals. Indeed, this population is known to have higher prevalence of cardiometabolic comorbidities and socioeconomic vulnerabilities. Studies among more ethnically and geographically diverse cohorts are needed to confirm our hypothesis concerning VOC 20H/501Y.V2. Third, we performed a description of changes in the characteristics of critically ill patients with Covid-19 in the first and second wave as a proxy for dominant lineage and we have individual-level data on lineage only for 23 critically-ill patients. However, during two days in the first half of February, all usable SARS-CoV-2 positive samples were screened and more than 80% of them (150/172) pointed to 20H/501Y.V2 variant. Fourth, we identified clinical and biological parameters to differentiate waves but we did not observe change in major outcomes as duration of invasive ventilation, ICU length of stay or mortality. Lastly, we could not assess statistically the association of the ICU overload and outcomes.

5. Conclusion

Our data described that emergence of SARS-CoV-2 VOC 20H/501Y.V2 in critically ill patients. It was associated with an increased severity of respiratory failure on admission and more risk for VAP without an increase of mortality. We hypothesized that the expected gain in survival brought by recent improvements in critical care management could have been mitigated by increased transmissibility of the new lineage leading to more severe patients on admission in ICU. The immunological role of VOC 20H/501Y.V2 in the propensity for VAP requires further investigations. Studies with geographically diverse cohorts and complete individual lineage data are needed to confirm our findings about this variant.

The authors thank Patrice COMBE, M.D. (Medical Biology Laboratory, Mayotte Hospital, Mamoudzou, Mayotte, France) for data concerning RTPCR. Moreover, the authors pay a great tribute to the Reunion and Mayotte hospital’s ICU teams involved during the health crisis.

Author contributions

PA, YB, RB, and OH designed the study. QM, CE, GML, ACM, OS, and BP acquired the data. PA and JB did the statistical analysis. PA, YB, and OH analyzed and interpreted the data. PA, YB, and OH drafted the manuscript. All authors critically reviewed the manuscript and approved the final report.

Conceptualization: Philippe Aries, Olivier Huet, Quentin Mathais, Camille Estagnasie, Renaud Blonde, Yvonnick Boue.

Data curation: Philippe Aries, Quentin Mathais, Camille Estagnasie, Gonzague Martin-Lecamp, Olivier Simon, Anne-Cécile Morvan, Bérénice Puech, Marion Subiros, Renaud Blonde, Yvonnick Boue.

Methodology: Philippe Aries, Olivier Huet, Julien Balicchi, Quentin Mathais, Camille Estagnasie, Gonzague Martin-Lecamp, Marion Subiros, Renaud Blonde, Yvonnick Boue.

Project administration: Philippe Aries, Yvonnick Boue.

Resources: Philippe Aries, Quentin Mathais, Yvonnick Boue.

Supervision: Philippe Aries, Olivier Huet, Renaud Blonde, Yvonnick Boue.

Validation: Philippe Aries, Olivier Huet, Renaud Blonde, Yvonnick Boue.

Visualization: Philippe Aries, Olivier Huet, Renaud Blonde.

Writing – original draft: Philippe Aries, Yvonnick Boue.

Writing – review & editing: Philippe Aries, Olivier Huet, Yvonnick Boue.

References

1. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed November 1, 2021.
2. SARS-CoV-2 Variant Classifications and Definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Accessed November 27, 2021.
3. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443.
4. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. Cold Spring Harbor Laboratory Press. 2020;2020.12.21.20248640.
5. Roquebert B, Trombert-Paolantoni S, Haim-Boukobza S, et al. The SARS-CoV-2 B.1.351 lineage (VOC [β]) is outgrowing the B.1.1.7 lineage (VOC [α]) in some French regions in April 2021. Euro Surveill. 2021;26.e2100447.
6. Jassat W, Mudara C, Ozougwu L, et al. Difference in mortality among individuals admitted to COVID-19 with the first and second waves in South Africa: a cohort study. Lancet Glob Health. 2021;9:e1216–e1225.
7. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Severity, criticality, and fatality of the SARS-CoV-2 Beta variant. Clin Infect Dis. 2021;cbab099.
24. Routsi C, Kokkoris S, Siempos I, et al. Fewer intubations but higher mortality among intubated coronavirus disease 2019 patients during the second than the first wave. Crit Care Explor. 2021;3:e531.

25. Chen H, Xie J, Su N, et al. Corticosteroid therapy is associated with improved outcome in critically ill patients with COVID-19 with hyper-inflamatory phenotype. Chest. 2021;159:1793–1802.

26. Jassat W, Mudara C, Ozoegwu U, et al. Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa. medRxiv. Cold Spring Harbor Laboratory Press. 2021;2021.03.09.21253184.

27. Madhara P, Wunsch H, Jha P, et al. Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples. Lancet Respir Med. 2021;9:322–4.

28. Damme WV, Dahake R, Delamou A, et al. The COVID-19 pandemic: diverse contexts; different epidemics—how and why? BMJ Global Health. 2020;5:e003098.

29. Carbomell R, Urgelles S, Rodriguez A, et al. Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: a multicentre retrospective cohort study. Lancet Respir Health. 2021;11:100243.

30. Bravata DM, Perkins AJ, Myers LJ, et al. Association of intensive care unit patient load and demand with mortality rates in US department of veterans affairs hospitals during the COVID-19 pandemic. JAMA Netw Open. 2021;4:e2034266.

31. Rosman H, Meir T, Somer J, et al. Hospital load and increased COVID-19 related mortality in Israel. Nat Commun. 2021;12:1904.

32. Ritter LA, Britton N, Heil EL, et al. The impact of corticosteroids on secondary infection and mortality in critically ill COVID-19 patients. J Intensive Care Med. 2021;36:1201–8.

33. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992–1000.e3.

34. Ratcliffe J, Nguyen D, Fish M, et al. Virological and serological characterization of critically ill patients with COVID-19 in the UK: interactions of viral load, antibody status and B.1.1.7 variant infection. J Infect Dis. 2021;224:395–605.

35. Rouzé A, Martin-Loeches I, Povoa P, et al; on behalf of the coVAPid study Group. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;47:188–98.

36. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996.

37. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47:60–73.

38. Florence S, Lebas J, Parizot I, et al. [Migration, health and access to care in Mayotte Island in 2007: lessons learned from a representative survey]. Rev Epidemiol Sante Publique. 2010;58:237–44.

39. Fan G, Yang Z, Lin Q, et al. Decreased case fatality rate of COVID-19 in the second than the first wave. Crit Care Explor. 2021;25:3.